C 0172Alternative Names: C-0172
Latest Information Update: 14 Feb 2008
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 19 May 2005 Phase-I clinical trials in Urinary incontinence in USA (unspecified route)